It has now been discovered that some B.1.1.7 coronaviruses in the UK also carry the E484K mutation.
To discover new mutations, British researchers reviewed 214,159 genomes of coronavirus, which the United Kingdom has sequenced as of 26 January. In its report, Public Health England stated that they had found 11 samples of the B1.1.7 E484K mutation.
Since that analysis, more of these viruses have come to light. NextStrain, a website where scientists collect and analyze coronavirus genomes, Now 16 B.1.1.7 identifies variants that carry the E484K mutation.
These B.1.1.7 coronaviruses gained mutation thanks to random duplication errors with multiplying inside people. The evolutionary tree of coronavirus suggests that 15 variants derive from a common ancestor that acquired the E484K mutation. Meanwhile the sixteenth edition has acquired the same mutation on its own.
Commenting on Monday’s report, Cristian Anderson, a virologist at the Scripps Research Institute in La Jepa, California, said it is impossible to say right now whether the E484K mutation is not only more contagious and more resistant to the vaccine, but will make these coronavuses . “It’s too early to predict what will happen, so we’ll have to wait for the data,” he said.
Just because the E484K mutation helps the B.1351 variant, which was initially found in South Africa, the average antibody does not mean it will do the same in other variants. This is because the mutation has no definite effect. The effect of a new mutation for one virus depends on the other mutation it already carries.
Currently more than 150 million people – about half the population – are eligible for vaccination. but Each state makes the final decision about who goes first. The country’s 21 million health care workers and three million residents of long-term care facilities were previously eligible. In mid-January, federal officials urged all states To open eligibility All adults 65 and older with medical conditions at high risk of becoming seriously ill or dying of Kovid-19. Adults in the general population are behind the line. If federal and state health officials can overcome bottlenecks in vaccine delivery, all 16 and older will become eligible by this spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It may be months before the vaccine becomes available to anyone under 16 months of age. Go to your state health website For up-to-date information about vaccination policies in your area
You should not give anything out of pocket to get vaccinated, Although you will be asked for insurance information. Even if you do not have insurance, you should be given the vaccine at no charge. Congress passed legislation this spring to prohibit insurers from sharing any costs, such as co-pays or deductibles. It provides additional protection from billing patients to pharmacies, doctors and hospitals, including those. Still, health experts worry that patients may be weak Leave the bills surprising them. This can happen to people who are charged with a doctor visit with a vaccine, or Americans who have certain types of health coverage that are not covered under the new regulations. If you receive your vaccine from a doctor’s office or urgent care clinic, talk to them about a possible hidden fee. To ensure that you do not get a surprise bill, the best bet is to get your vaccine delivered to the health department’s vaccination site or local pharmacy after shots become more widely available.
It is to be determined. It is possible that the Kovid-19 vaccination will become an annual phenomenon like the flu pill. Or it may be that the benefits of the vaccine stay for more than a year. We will have to wait to see how durable the protection from vaccines is. To determine this, researchers are going to monitor vaccinated people to look for “cases of success” – people who get sick from Kovid-19 despite being vaccinated. This is a sign of weakening safety and will give researchers clues about how long the vaccine lasts. They will monitor the levels of antibodies and T cells in the blood of vaccinated people to determine if and when a booster shot may be required. It is predictable that people may need boosters every few months, once a year or only a few years. It is just a matter of waiting for the data.
But a The report was posted online on Tuesday., Ravi Gupta, a virologist at the University of Cambridge, and his colleagues reported an experiment they ran to address this question. They combined the E484K mutation with other major mutations found in the B.1.1.7 variant, initially found in Britain. The addition of the E484K mutation made it difficult for antibodies to block the virus. Researchers write that they have “seen a significant loss of neutralizing activity.”
However, Drs. Gupta and his colleagues used antibodies taken from people who had received just two doses of the Pfizer-Bayonet Tech vaccine. It remains to be seen whether type B.1.1.7 with the new mutation, E484K, can remove antibodies after complete immunization.